SUTRO BIOPHARMA, INC. Income Statement
STRO|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$62M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$238M
FY2025
Net Income
-$227M
FY2025
SUTRO BIOPHARMA, INC. reported $62M in revenue and $227M in net loss for FY2025. Revenue has grown at a 0.5% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $62.0M | $67.8M | $61.9M | $42.7M | $42.7M | $38.4M | $51.7M | $59.7M |
| SG&A Expense | $48.5M | $59.5M | $56.0M | $36.8M | $32.6M | $21.4M | $16.4M | $14.8M |
| R&D Expense | $252.0M | $137.2M | $104.4M | $77.0M | $65.6M | $54.3M | $54.6M | $43.5M |
| Operating Income | -$238.5M | -$128.9M | -$98.5M | -$71.1M | -$55.5M | -$37.2M | -$19.3M | $1.4M |
| Interest Expense | - | - | $2.6M | $2.3M | $1.1M | $1.6M | $600.0K | $0 |
| Income Tax | $2.4M | $2.5M | $2.5M | $103.0K | $0 | $0 | $0 | $0 |
| Net Income | -$227.5M | -$119.2M | -$105.5M | -$119.2M | -$55.7M | -$35.3M | -$19.7M | $1.7M |
| EPS (Basic) | -$29.40 | -$2.35 | -$2.29 | -$0.99 | - | $1.00 | - | - |
| EPS (Diluted) | -$29.40 | -$2.35 | -$2.29 | -$0.99 | -$2.43 | $0.94 | -$43.95 | $0.00 |
| Shares Outstanding | 8.3M | 61.0M | 57.5M | 46.3M | 45.8M | 23.1M | 22.8M | 465.3K |
| Operating Margin | -384.3% | -190.3% | -159.2% | -166.3% | -129.8% | -96.9% | -37.3% | 2.3% |
| Profit Margin | -366.6% | -175.9% | -170.6% | -279.0% | -130.4% | -91.9% | -38.0% | 2.9% |